ID

31541

Beschreibung

Immediate Versus Deferred Androgen Deprivation Therapy,Goserelin for Recurrent Prostate Cancer After Radical Radiotherapy; ODM derived from: https://clinicaltrials.gov/show/NCT00439751

Link

https://clinicaltrials.gov/show/NCT00439751

Stichworte

Versionen (1)
  1. 03.09.18 03.09.18 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

3. September 2018

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Prostate Cancer NCT00439751

Englisch

Eligibility Prostate Cancer NCT00439751

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. males over 18 years of age with histological confirmation of adenocarcinoma of the prostate.
Beschreibung

Age | Adenocarcinoma of prostate

Datentyp

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2]
C0007112
2. biochemical progression after radical radiotherapy with a total prostate dose > 52 gy.
Beschreibung

Therapeutic radiology procedure Radical Prostate Total Dose | Progression Biochemical

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1522449
UMLS CUI [1,2]
C0439807
UMLS CUI [1,3]
C0033572
UMLS CUI [1,4]
C2986497
UMLS CUI [2,1]
C0242656
UMLS CUI [2,2]
C0205474
in patients without previous radical prostatectomy, biochemical progression is defined as psa in the range of nadir + 2 ng/ml (phoenix definition) to ≤ 6 ng/ml (this psa must be within 30 days of randomization).
Beschreibung

Radical prostatectomy Absent | Progression Biochemical | Prostate specific antigen measurement Nadir

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0194810
UMLS CUI [1,2]
C0332197
UMLS CUI [2,1]
C0242656
UMLS CUI [2,2]
C0205474
UMLS CUI [3,1]
C0201544
UMLS CUI [3,2]
C1708760
in patients with previous radical prostatectomy, biochemical progression is defined as a rising psa (at least 2 values) in the range of 0.4 ng/ml to ≤ 3 ng/ml (most recent psa must be within 30 days of randomization).
Beschreibung

Radical prostatectomy | Progression Biochemical | Raised prostate specific antigen

Datentyp

boolean

Alias
UMLS CUI [1]
C0194810
UMLS CUI [2,1]
C0242656
UMLS CUI [2,2]
C0205474
UMLS CUI [3]
C0178415
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. patients who are within 4 years of their brachytherapy implantation date.
Beschreibung

Brachytherapy

Datentyp

boolean

Alias
UMLS CUI [1]
C0006098
2. patients with medical conditions in which goserelin or bicalutamide is contraindicated in the opinion of the supervising oncologist or urologist.
Beschreibung

Medical condition Contraindicated Goserelin | Medical condition Contraindicated Bicalutamide

Datentyp

boolean

Alias
UMLS CUI [1,1]
C3843040
UMLS CUI [1,2]
C1444657
UMLS CUI [1,3]
C0120107
UMLS CUI [2,1]
C3843040
UMLS CUI [2,2]
C1444657
UMLS CUI [2,3]
C0285590
3. patients with another active malignancy or malignancy treatment within 5 years (basal or squamous cell skin cancers are not excluded from this trial).
Beschreibung

Cancer Other | Cancer treatment Other | Exception Basal cell carcinoma | Exception Squamous cell carcinoma of skin

Datentyp

boolean

Alias
UMLS CUI [1]
C1707251
UMLS CUI [2,1]
C0920425
UMLS CUI [2,2]
C0205394
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0007117
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0553723
4. patients with geographic inaccessibility precluding them from necessary follow-up.
Beschreibung

Geographic Factors Exclude Follow-up

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0017444
UMLS CUI [1,2]
C0332196
UMLS CUI [1,3]
C3274571
5. failure to provide written informed consent.
Beschreibung

Informed Consent failed

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0021430
UMLS CUI [1,2]
C0231175
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Prostate Cancer NCT00439751

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Age | Adenocarcinoma of prostate
Item
1. males over 18 years of age with histological confirmation of adenocarcinoma of the prostate.
boolean
C0001779 (UMLS CUI [1])
C0007112 (UMLS CUI [2])
Therapeutic radiology procedure Radical Prostate Total Dose | Progression Biochemical
Item
2. biochemical progression after radical radiotherapy with a total prostate dose > 52 gy.
boolean
C1522449 (UMLS CUI [1,1])
C0439807 (UMLS CUI [1,2])
C0033572 (UMLS CUI [1,3])
C2986497 (UMLS CUI [1,4])
C0242656 (UMLS CUI [2,1])
C0205474 (UMLS CUI [2,2])
Radical prostatectomy Absent | Progression Biochemical | Prostate specific antigen measurement Nadir
Item
in patients without previous radical prostatectomy, biochemical progression is defined as psa in the range of nadir + 2 ng/ml (phoenix definition) to ≤ 6 ng/ml (this psa must be within 30 days of randomization).
boolean
C0194810 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0242656 (UMLS CUI [2,1])
C0205474 (UMLS CUI [2,2])
C0201544 (UMLS CUI [3,1])
C1708760 (UMLS CUI [3,2])
Radical prostatectomy | Progression Biochemical | Raised prostate specific antigen
Item
in patients with previous radical prostatectomy, biochemical progression is defined as a rising psa (at least 2 values) in the range of 0.4 ng/ml to ≤ 3 ng/ml (most recent psa must be within 30 days of randomization).
boolean
C0194810 (UMLS CUI [1])
C0242656 (UMLS CUI [2,1])
C0205474 (UMLS CUI [2,2])
C0178415 (UMLS CUI [3])
Item Group
C0680251 (UMLS CUI)
Brachytherapy
Item
1. patients who are within 4 years of their brachytherapy implantation date.
boolean
C0006098 (UMLS CUI [1])
Medical condition Contraindicated Goserelin | Medical condition Contraindicated Bicalutamide
Item
2. patients with medical conditions in which goserelin or bicalutamide is contraindicated in the opinion of the supervising oncologist or urologist.
boolean
C3843040 (UMLS CUI [1,1])
C1444657 (UMLS CUI [1,2])
C0120107 (UMLS CUI [1,3])
C3843040 (UMLS CUI [2,1])
C1444657 (UMLS CUI [2,2])
C0285590 (UMLS CUI [2,3])
Cancer Other | Cancer treatment Other | Exception Basal cell carcinoma | Exception Squamous cell carcinoma of skin
Item
3. patients with another active malignancy or malignancy treatment within 5 years (basal or squamous cell skin cancers are not excluded from this trial).
boolean
C1707251 (UMLS CUI [1])
C0920425 (UMLS CUI [2,1])
C0205394 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0007117 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C0553723 (UMLS CUI [4,2])
Geographic Factors Exclude Follow-up
Item
4. patients with geographic inaccessibility precluding them from necessary follow-up.
boolean
C0017444 (UMLS CUI [1,1])
C0332196 (UMLS CUI [1,2])
C3274571 (UMLS CUI [1,3])
Informed Consent failed
Item
5. failure to provide written informed consent.
boolean
C0021430 (UMLS CUI [1,1])
C0231175 (UMLS CUI [1,2])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video